Microbix identifies specific proteins that allow X and Y sperm cells to be separated
Microbix Biosystems Inc. announced that it is has made a significant discovery that takes it a major step forward in commercializing its animal reproduction technology. The Company has been able to identify specific proteins that allow female-producing and male-producing sperm cells to be separated, and has also developed the monoclonal antibodies that will be used to commercialize this process. According to the company, this is the first time that sex-specific proteins have been positively identified. Microbix has filed a provisional patent on this discovery.
This is the second important milestone in the Semen Sexing Technology(TM) (SST(TM)) development program. Microbix obtained this technology through its acquisition of Sequent Biotechnologies Inc. in September, 2005. Under the terms of that agreement, Sequent's founders are to receive $3 million in common stock of Microbix, payment being staged and contingent upon the achievement of certain milestones that enable entry into the marketplace. With this announcement, Sequent's founders have been issued 1,821,862 common shares of Microbix, representing half of the total potential payment.
Weitere News aus dem Ressort Forschung & Entwicklung
Diese Produkte könnten Sie interessieren
Antibody Stabilizer von CANDOR Bioscience
Protein- und Antikörperstabilisierung leicht gemacht
Langzeitlagerung ohne Einfrieren – Einfache Anwendung, zuverlässiger Schutz
DynaPro NanoStar II von Wyatt Technology
NanoStar II: DLS und SLS mit Touch-Bedienung
Größe, Partikelkonzentration und mehr für Proteine, Viren und andere Biomoleküle
